Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

Artificial intelligence-enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications.

Frontiers in oncology·2026
Same author

Genome-wide SNP-based Profiling of Loss of Heterozygosity Reveals Distinct Molecular Subgroup-specific Patterns in Gastrointestinal Stromal Tumors (GIST).

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Handling missing modalities in multimodal survival prediction for non-small cell lung cancer.

NPJ digital medicine·2026
Same author

Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors study.

British journal of cancer·2026
Same author

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Bisphosphonate anticancer activity.

Giuseppe Tonini, Bruno Vincenzi, Daniele Santini

    Expert Opinion on Pharmacotherapy
    |March 10, 2011
    PubMed
    Summary
    This summary is machine-generated.

    Bone metastases significantly impact cancer patient survival and quality of life. Emerging molecular targets and ongoing clinical trials highlight the critical need for effective bone metastasis treatments.

    More Related Videos

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
    06:00

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

    Published on: September 13, 2017

    Related Experiment Videos

    Last Updated: Jun 3, 2026

    Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
    13:08

    Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

    Published on: September 9, 2011

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
    06:00

    Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

    Published on: September 13, 2017

    Area of Science:

    • Oncology
    • Cancer Metastasis Research
    • Bone Biology

    Background:

    • Bone metastases are a significant cause of morbidity and mortality in cancer patients.
    • Metastasis remains a poorly understood aspect of carcinogenesis.
    • Understanding the mechanisms of bone metastasis is crucial for improving patient outcomes.

    Discussion:

    • Several molecular pathways, including RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, and Src, are implicated in bone metastasis.
    • These pathways represent promising therapeutic targets for intervention.
    • Preclinical and clinical trials are actively investigating these targets.

    Key Insights:

    • Clinical trial results underscore the importance of targeting bone metastases.
    • Effective treatment and prevention strategies are needed across diverse cancer populations.
    • Targeting specific molecular pathways shows promise in managing bone metastases.

    Outlook:

    • Continued research into the molecular underpinnings of bone metastasis is essential.
    • Advancements in clinical trials are expected to yield new therapeutic options.
    • A multi-targeted approach may be necessary for comprehensive management of bone metastases.